PFKFB3 and breast cancer: Moreover, knockdown of PFKFB2 in p53 wild-type breast cancer cells enhanced paclitaxel sensitivity [48], and inhibition of PFKFB3 and PFKFB4 sensitized ER-positive breast cancer cells to ER-targeting therapies [49].